

BLACK BOX WARNING

KISUNLA

donanemab

What is KiSunla?

An amyloid-beta direct antibody that is indicated for the treatment of early Alzheimer's Disease

Who is KiSunla for?

For those with diagnosed Alzheimer's Disease, experiencing symptoms in its early stage




How does KiSunla work?

Alzheimer's disease causes amyloid plaque buildup on the neurons in the brain, affecting cognitive and functional abilities.

KiSunla targets those plaques, breaks it up, and destroys them. This results in a slower progression of the Alzheimer's Disease.

Dosages and Routes

KiSunla is given via IV infusion over 30 minutes given every 4 weeks



(Food and Drug Administration)

Indication

Drug

Contraindications

Hypersensitivity

donor

Infusion

Lab

PET Scan

Confirms

Genotyping

Assesses

gene, which

(a potential

Brain MRI

To monitor

Swelling,

ARIA